A novel de novo SCN1A missense mutation in Severe Myoclonic Epilepsy Borderland
Nicola Specchio1, Marina Trivisano, Martina Balestri
1Division of Neurology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. nicola.specchio@opbg.net
Insights
A novel SCN1A gene mutation was identified in a patient with Severe Myoclonic Epilepsy Borderland (SMEB). This discovery advances understanding of the genetic basis of this rare epilepsy syndrome.
Area of Science:
- Genetics
- Neurology
- Epilepsy Research
Background:
- Severe Myoclonic Epilepsy Borderland (SMEB) is a rare epilepsy syndrome.
- Genetic mutations in the SCN1A gene are implicated in various epilepsy forms.
Observation:
- A 3.5-year-old female presented with prolonged febrile seizures, generalized tonic-clonic seizures, atonic seizures, and atypical absences.
- Clinical presentation was suggestive of SMEB, with normal cognitive and motor development.
Findings:
- A novel de novo missense mutation, c.4183 G>T (p.D1396Y), was identified in exon 21 of the SCN1A gene.
- This mutation involves a heterozygous replacement of guanine with thymine.
Implications:
- This finding contributes to the growing list of SCN1A mutations associated with SMEB.
- Further research is needed to establish definitive genotype-phenotype correlations for SCN1A-related epilepsies, considering potential involvement of other factors.
Abstract:
In this report we describe a novel missense SCN1A mutation in a patient affected by Severe Myoclonic Epilepsy Borderland (SMEB). This three and a half year-old female patient experienced prolonged febrile seizures at the age of 14 months, followed by generalized tonic-clonic seizures, atonic seizures, atypical absences almost in a cluster and triggered by fever. Cognitive and motor development was normal. The case was suggestive for SMEB. SCN1A analysis revealed an unknown de novo point mutation: a heterozygous replacement of nucleotide G with nucleotide T in position 4183 of the coding region of the gene (c.4183 G>T) in exon 21. This mutation causes the replacement of aspartic acid with tyrosine in 1395 (p.D1396Y). Even if other SCN1A missense mutations localized in the same region are associated to SMEB, a definite genotype-phenotype correlation has not yet been found, probably because other factors are involved in the pathogenesis of this type of epilepsy.
Related Concept Videos
Huntington Disease l: Introduction
Single Nucleotide Polymorphisms-SNPs
Sex-linked Disorders
Point and Frameshift Mutations
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Animal Mitochondrial Genetics


